<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330704</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-43653</org_study_id>
    <nct_id>NCT03330704</nct_id>
  </id_info>
  <brief_title>Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation</brief_title>
  <official_title>Randomized Controlled Trial for the Use of Patient Tailored Balanced Hypertonic Solutions in Patients With Cerebral Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients with traumatic brain injuries (including strokes, blood clots, or other brain
      injuries) are given concentrated salt water solutions (hypertonic saline) in order to treat
      brain swelling (cerebral edema). Current therapies consist of a mixture of sodium and
      chloride, which can lead to high levels of serum chloride and increased total body water.
      High levels of chloride can cause acidosis, which can cause the body to function
      sub-optimally. Therefore, the investigators are proposing to use two concentrated solutions
      in these patients at the same time that will allow for a lower total volume of solution
      administration and reduce the rise in chloride to prevent acidosis. The main outcome will
      therefore be the patients sodium level, chloride level and serum pH.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 8, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 8, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total volume of intravenous hypertonic fluid administered to the patient</measure>
    <time_frame>The fluid will be infused until the new serum sodium goal is achieved. This outcome measure will be assessed 1 week after study enrollment</time_frame>
    <description>Total hypertonic fluid volume administered to each group of patients measured in milliliters of fluid.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine output</measure>
    <time_frame>Urine output during active hypertonic fluid infusion will be measured. This outcome measure will be assessed 1 week after study enrollment</time_frame>
    <description>Urine output will be collected and measured quantitatively in milliliter units.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cerebral Edema</condition>
  <condition>Saline Solution, Hypertonic</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive 3% hypertonic sodium chloride for the management of their cerebral edema. 3% Sodium Chloride is the generic name of this intravenous fluid preparation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balanced Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will undergo two simultaneous infusions. 23.4% sodium chloride and 8.4% sodium bicarbonate will be infused at the same time in various ratios for management of cerebral edema with a balanced approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% Sodium Chloride</intervention_name>
    <description>3% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>23.4% Sodium Chloride</intervention_name>
    <description>23.4% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure</description>
    <arm_group_label>Balanced Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8.4% Sodium Bicarbonate</intervention_name>
    <description>8.4% sodium bicarbonate will be infused into patients for the treatment or prevention of raised intracranial pressure</description>
    <arm_group_label>Balanced Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to consent

          -  18 years or older

          -  English speaking

          -  Clinical indication (intracranial hypertension from cerebral edema) for hypertonic
             fluid administration

        Exclusion Criteria:

          -  Fails to consent

          -  &lt; 18 years old

          -  Hypertonic therapy not indicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Gostine, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew L Gostine, MD, MBA</last_name>
    <phone>(650) 723-4000</phone>
    <email>gostine@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier Lorenzo, MD</last_name>
    <phone>(650) 723-4000</phone>
    <email>javierl@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew L Gostine, MD, MBA</last_name>
      <phone>650-723-4000</phone>
      <email>gostine@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Javier Lorenzo, MD</last_name>
      <phone>(650) 723-4000</phone>
      <email>javierl@stanford.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wilcox CS. Regulation of renal blood flow by plasma chloride. J Clin Invest. 1983 Mar;71(3):726-35.</citation>
    <PMID>6826732</PMID>
  </reference>
  <reference>
    <citation>Toung TJ, Nyquist P, Mirski MA. Effect of hypertonic saline concentration on cerebral and visceral organ water in an uninjured rodent model. Crit Care Med. 2008 Jan;36(1):256-61.</citation>
    <PMID>18090381</PMID>
  </reference>
  <reference>
    <citation>Diringer MN, Zazulia AR. Osmotic therapy: fact and fiction. Neurocrit Care. 2004;1(2):219-33. Review.</citation>
    <PMID>16174920</PMID>
  </reference>
  <reference>
    <citation>Erdman MJ, Riha H, Bode L, Chang JJ, Jones GM. Predictors of Acute Kidney Injury in Neurocritical Care Patients Receiving Continuous Hypertonic Saline. Neurohospitalist. 2017 Jan;7(1):9-14. doi: 10.1177/1941874416665744. Epub 2016 Aug 29.</citation>
    <PMID>28042364</PMID>
  </reference>
  <reference>
    <citation>Neavyn MJ, Boyer EW, Bird SB, Babu KM. Sodium acetate as a replacement for sodium bicarbonate in medical toxicology: a review. J Med Toxicol. 2013 Sep;9(3):250-4. doi: 10.1007/s13181-013-0304-0. Review.</citation>
    <PMID>23636658</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrew Gostine</investigator_full_name>
    <investigator_title>Clinical Instructor, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

